‘Gamechanger’ HIV prevention drug to be made available cheaply in 120 countries
Gilead Sciences says it has signed agreements with six manufacturers to make and sell generic lenacapavir in 120 “high-incidence, resource-limited” countries. Lenacapavir, given as a twice-yearly injection, has shown strong results for HIV prevention. It stopped infection in a trial involving girls and women in South Africa and Uganda, and offered almost complete protection in a second trial that mainly involved men across Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the U.S.
‘Gamechanger’ HIV prevention drug to be made available cheaply in 120 countries Read more